Daehwa Pharmaceutical: Liporaxel Breast Cancer Approval and Q1 Results
Liporaxel (oral paclitaxel) received additional breast cancer indication approval (2026.05.13, MFDS)
China NMPA approved gastric cancer marketing and NRDL listing (effective 2026.01.01); Chinese partner submitted breast cancer approval
Consolidated revenue: 37.0B KRW (+1% YoY), operating profit: 0.45B KRW (down from 1.13B KRW in prior year), net loss attributable to parent: 0.25B KRW (narrowed from 0.41B KRW loss)
Separate revenue: 27.8B KRW (up from 26.6B KRW), operating profit: 0.97B KRW (up from 0.1B KRW), net profit: 0.45B KRW (swung to profit)
R&D expenses: 2.32B KRW (6.27% of revenue)
Total assets: 222.3B KRW, liabilities: 137.3B KRW, equity: 85.1B KRW
Changes in capital: disposal of treasury shares and issuance of exchangeable bonds
Cash and cash equivalents: 5.5B KRW (up from 1.4B KRW at year-end)
Consolidated net loss continues due to subsidiary losses